File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Paediatric medicines research in the UK: How to move forward?

TitlePaediatric medicines research in the UK: How to move forward?
Authors
KeywordsChemicals And Cas Registry Numbers
Issue Date2003
PublisherAdis International Ltd. The Journal's web site is located at http://drugsafety.adisonline.com/
Citation
Drug Safety, 2003, v. 26 n. 8, p. 529-537 How to Cite?
AbstractThere have been numerous studies to show that many of the medicines used in children are used off-label or are unlicensed for use in children. When children are prescribed unlicensed and off-label medications, some people may see them as unknowing participants in informal and uncontrolled experiments. However, the licensing status of a drug can be seen as a by-product of the real issues: the safety, efficacy and quality of these medicines in the current licensing system. It is important to conduct research in order to provide high quality data regarding safety and efficacy to support evidence-based paediatric prescribing. Clinical trials will always be an invaluable means of acquiring vital information about a drug; but when it comes to children, we may find that these trials are not always practical for technical, ethical and financial reasons; therefore, it is important to explore other methodologies in paediatric medicines research. Pharmacoepidemiological and prospective cohort studies could provide vital safety and efficacy data on paediatric medicines; however, resources need to be invested in the methodological research. Paediatric drug formulation research is under-resourced and under-valued, and, unfortunately, fatal and serious adverse reactions due to inappropriate formulations have been reported in many instances. Paediatric medication is a complex problem; we need to use all available tools for research on safety, efficacy and formulation. The reason for lack of progress in paediatric drug research is most likely due to lack of resources and research capacity. The industry and government should work together and invest more money in paediatric drug research. Finally, regulatory authorities, healthcare professionals and academics need to rethink the research strategy in order to provide better medicines for children.
Persistent Identifierhttp://hdl.handle.net/10722/132905
ISSN
2015 Impact Factor: 3.206
2015 SCImago Journal Rankings: 1.359
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorWong, Ien_HK
dc.contributor.authorSweis, Den_HK
dc.contributor.authorCope, Jen_HK
dc.contributor.authorFlorence, Aen_HK
dc.date.accessioned2011-04-04T07:57:54Z-
dc.date.available2011-04-04T07:57:54Z-
dc.date.issued2003en_HK
dc.identifier.citationDrug Safety, 2003, v. 26 n. 8, p. 529-537en_HK
dc.identifier.issn0114-5916en_HK
dc.identifier.urihttp://hdl.handle.net/10722/132905-
dc.description.abstractThere have been numerous studies to show that many of the medicines used in children are used off-label or are unlicensed for use in children. When children are prescribed unlicensed and off-label medications, some people may see them as unknowing participants in informal and uncontrolled experiments. However, the licensing status of a drug can be seen as a by-product of the real issues: the safety, efficacy and quality of these medicines in the current licensing system. It is important to conduct research in order to provide high quality data regarding safety and efficacy to support evidence-based paediatric prescribing. Clinical trials will always be an invaluable means of acquiring vital information about a drug; but when it comes to children, we may find that these trials are not always practical for technical, ethical and financial reasons; therefore, it is important to explore other methodologies in paediatric medicines research. Pharmacoepidemiological and prospective cohort studies could provide vital safety and efficacy data on paediatric medicines; however, resources need to be invested in the methodological research. Paediatric drug formulation research is under-resourced and under-valued, and, unfortunately, fatal and serious adverse reactions due to inappropriate formulations have been reported in many instances. Paediatric medication is a complex problem; we need to use all available tools for research on safety, efficacy and formulation. The reason for lack of progress in paediatric drug research is most likely due to lack of resources and research capacity. The industry and government should work together and invest more money in paediatric drug research. Finally, regulatory authorities, healthcare professionals and academics need to rethink the research strategy in order to provide better medicines for children.en_HK
dc.languageengen_US
dc.publisherAdis International Ltd. The Journal's web site is located at http://drugsafety.adisonline.com/en_HK
dc.relation.ispartofDrug Safetyen_HK
dc.subjectChemicals And Cas Registry Numbersen_US
dc.titlePaediatric medicines research in the UK: How to move forward?en_HK
dc.typeArticleen_HK
dc.identifier.emailWong, I: wongick@hku.hken_HK
dc.identifier.authorityWong, I=rp01480en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.2165/00002018-200326080-00001en_HK
dc.identifier.pmid12825967-
dc.identifier.scopuseid_2-s2.0-0037635309en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0037635309&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume26en_HK
dc.identifier.issue8en_HK
dc.identifier.spage529en_HK
dc.identifier.epage537en_HK
dc.identifier.isiWOS:000183492500001-
dc.publisher.placeNew Zealanden_HK
dc.identifier.scopusauthoridWong, I=7102513915en_HK
dc.identifier.scopusauthoridSweis, D=6505801311en_HK
dc.identifier.scopusauthoridCope, J=55066199900en_HK
dc.identifier.scopusauthoridFlorence, A=7102444960en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats